MRKR — Marker Therapeutics Share News
0.000.00%
Last trade - 00:00- $16.01m
- $4.68m
- $3.55m
Brief: Marker Therapeutics Reports Fiscal Year 2022 Corporate And Financial Results
Marker Therapeutics Inc expected to post a loss of 100 cents a share - Earnings Preview
Brief: Marker Therapeutics Inc Filed 1-For-10 Reverse Stock Split
Brief: Marker Therapeutics Inc Files For Offer And Sale Of Up To 25.8 Million Shares Of Common Stock By Lincoln Park Capital Fund - SEC Filing
Brief: Marker Therapeutics, Lincoln Park Capital Enters Into Share Purchase Agreement For Up To $25 Mln
U.S. STOCKS ON THE MOVE-Caterpillar, Coinbase, WW International
U.S. STOCKS ON THE MOVE-Best Buy, Warner Music, Abercrombie & Fitch
U.S. STOCKS ON THE MOVE-Energy firms, gold miners, Analog Devices
Marker Therapeutics gains as FDA allows pancreatic cancer therapy trial
Brief: Marker Therapeutics Announces FDA Clearance Of Ind For MT-601, Its Six-Antigen T Cell Therapy For The Treatment Of Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Marker Therapeutics Reports Q3 2022 Operating And Financial Results
Marker Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Marker Therapeutics, Mayo Mutually Agree To Terminate Patent & Know-How License Agreement
Marker Therapeutics gains on U.S. FDA grant for blood cancer therapy trial
Brief: Marker Therapeutics Awarded $2 Million Grant From U.S. FDA To Support Marker’S Phase 2 Artemis Trial Of MT-401 In Post-Transplant Aml
Brief: Marker Therapeutics Reports Q2 2022 Operating And Financial Results
U.S. STOCKS ON THE MOVE-Signify Health, Tesla, Crypto firms
U.S. STOCKS ON THE MOVE-Energy firms, Retail chatter, MoneyGram